CHOICE I Study – LDL-C Efficacy 300 mg Q4W/150 mg Q2W

On top of maximally tolerated statins,

PRALUENT® (alirocumab) 300 mg Q4W: A once-monthly starting dose option with powerful LDL-C reduction1

  • PRALUENT once-monthly 300-mg dose: Administered as 2 consecutive, subcutaneous 150-mg injections at 2 different injection sites every 4 weeks1
  • At week 24: The treatment difference between PRALUENT 300 mg Q4W/150 mg Q2W and placebo in mean percent change in LDL-C from baseline was -56%1
    • – The treatment difference between PRALUENT 75 mg Q2W/150 mg Q2W and placebo in mean percent change in LDL-C from baseline was -48%
  • ASCVD population: Overall, 64% of patients had clinical ASCVD1
  • For patients receiving PRALUENT 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose, since in some patients LDL-C can vary considerably between doses with this regimen
  • The once-monthly (Q4W) 300 mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms
View examples of patients with ASCVD  

NEXT: PRALUENT LDL-C Efficacy 75 mg/150 mg (in HeFH)

References:
  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.
  2. Data on file, Sanofi/Regeneron.

Download Resources